Compare SPSC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPSC | PHVS |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2009 | 2020 |
| Metric | SPSC | PHVS |
|---|---|---|
| Price | $54.99 | $31.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $96.80 | $41.82 |
| AVG Volume (30 Days) | ★ 541.4K | 329.9K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.59 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $220,566,000.00 | N/A |
| Revenue This Year | $8.85 | N/A |
| Revenue Next Year | $7.37 | N/A |
| P/E Ratio | $103.83 | ★ N/A |
| Revenue Growth | ★ 14.11 | N/A |
| 52 Week Low | $49.04 | $16.00 |
| 52 Week High | $143.55 | $33.33 |
| Indicator | SPSC | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 49.69 | 58.44 |
| Support Level | $52.67 | $24.55 |
| Resistance Level | $59.85 | $33.33 |
| Average True Range (ATR) | 2.22 | 1.33 |
| MACD | 0.21 | 0.15 |
| Stochastic Oscillator | 47.65 | 82.35 |
SPS Commerce Inc is a provider of cloud-based supply chain management services for retailers, grocers, distributors, suppliers, and logistics firms to increase supply chain performance, optimize inventory levels and sell-through, reduce operational costs, improve order visibility, and satisfy consumer demands for a seamless omnichannel experience. Its solutions are delivered through the SPS Commerce platform and provide integrations and retail performance analytics to its customers. The company has one operating segment Supply Chain Management Solutions, that derives revenues from customers by providing access to cloud-based supply chain management services, primarily under subscription-based service arrangements.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.